HUMANIZED ANTI-VEGFR2 ANTIBODY AND APPLICATION THEREOF

Provided is a humanized anti-VEGFR2 antibody drug. Also provided are a nucleic acid sequence (comprising a heavy/light chain variable region) encoding the antibody, a vector containing the nucleic acid sequence, a pharmaceutical composition, and a kit. The antibody can specifically bind to the sixth structural domain of VEGFR2, exerts a function independent of ligand VEGF-A, and can directly inhibit VEGFR2 from forming a dimer, thereby blocking tyrosine residue phosphorylation caused by the dimerization of an intracellular domain of VEGFR2 and a downstream signaling pathway. In addition, the antibody keeps a function of partially blocking VEGF-C and VEGF-D, and thus has a better angiogenesis inhibition function. The antibody can also activate the occurrence of an antibody-dependent cell-mediated cytotoxicity (ADCC) reaction in NK cells, inhibits tumor growth and tumor metastases, and can be used for clinically treating melanomas. L'invention concerne un médicament à base d'anticorps humanisé anti-VEGFR2. L'in